Jake Green, 75, of Winchester, Ky., learned in 1987 that he had myasthenia gravis, a rare degenerative disease that attacks the nerves leading to muscles. Since then, the cost of a month's supply of Mestinon, the drug produced by Switzerland's Hoffman-LaRoche that helps control his disorder, has jumped from $65 to $136. In testimony before Congress last November, Green told the Senate Special Committee on Aging, "I fear the day when I will not be able to afford to purchase the medicine which is keeping me alive."
Barbara Connell heads the Daystar Care Center, a nursing home in Cairo, Ill. Her...
To continue reading:
or
Log-In
